These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9876554)

  • 21. Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.
    De Zordi N; Moneghini M; Kikic I; Grassi M; Del Rio Castillo AE; Solinas D; Bolger MB
    Eur J Pharm Biopharm; 2012 May; 81(1):131-41. PubMed ID: 22266263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disintegration of sublingual tablets: proposal for a validated test method and acceptance criterion.
    Weda M; van Riet-Nales DA; van Aalst P; de Kaste D; Lekkerkerker JF
    Pharmeur Sci Notes; 2006 Dec; 2006(2):41-4. PubMed ID: 17691213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
    Freerks L; Sommerfeldt J; Löper PC; Klein S
    Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance.
    Deng G; Ashley AJ; Brown WE; Eaton JW; Hauck WW; Kikwai LC; Liddell MR; Manning RG; Munoz JM; Nithyanandan P; Glasgow MJ; Stippler E; Wahab SZ; Williams RL
    Pharm Res; 2008 May; 25(5):1100-9. PubMed ID: 18172581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of SBA-15 for furosemide oral delivery enhancement.
    Ambrogi V; Perioli L; Pagano C; Marmottini F; Ricci M; Sagnella A; Rossi C
    Eur J Pharm Sci; 2012 May; 46(1-2):43-8. PubMed ID: 22365882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of nitroglycerin tablets submitted by U.S. hospitals.
    Crabbs WC; Dow ML; Juhl YH; Page DP
    Am J Hosp Pharm; 1983 Dec; 40(12):2170-5. PubMed ID: 6419589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
    Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
    Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosage variability of veterinary drug products, containing furosemide, linked to tablet splitting.
    Maggi L; Friuli V; Perugini P; Musitelli G; Venco L
    Open Vet J; 2021; 11(3):471-482. PubMed ID: 34722213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there variability in drug release and physical characteristics of amiodarone chloride from different commercially available tablets? Possible therapeutic implications.
    Ngo SN; Barnes T
    Int J Pharm Pract; 2010 Aug; 18(4):245-8. PubMed ID: 20636678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry.
    Ciavarella AB; Khan MA; Gupta A; Faustino PJ
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):523-532. PubMed ID: 27974592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of batch age on potency and dissolution of levothyroxine sodium tablets: impact of BP and USP monograph differences on dissolution results.
    Abou-Taleb BA; Nounou MI; Khalafallah N; Khalil S
    Drug Dev Ind Pharm; 2018 Nov; 44(11):1762-1769. PubMed ID: 29973090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmaceutical and biological availability of commercial preparations of furosemide.
    Stüber W; Mutschler E; Steinbach D
    Arzneimittelforschung; 1982; 32(6):693-7. PubMed ID: 6889429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chemical and pharmaceutical equivalence of sulphadoxine/pyrimethamine tablets sold on the Tanzanian market.
    Hebron Y; Tettey JN; Pournamdari M; Watson DG
    J Clin Pharm Ther; 2005 Dec; 30(6):575-81. PubMed ID: 16336290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality Testing of Difficult-to-Make Prescription Pharmaceutical Products Marketed in the US.
    Fisher AC; Viehmann A; Ashtiani M; Friedman RL; Buhse L; Kopcha M; Woodcock J
    JAMA Netw Open; 2020 Aug; 3(8):e2013920. PubMed ID: 32833019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioavailability of seven furosemide tablets in man.
    Straughn AB; Wood GC; Raghow G; Meyer MC
    Biopharm Drug Dispos; 1986; 7(2):113-20. PubMed ID: 3708119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of medicines for Cardio-Vascular Diseases (CVDs) in the Ethiopian border with Kenya: The case of enalapril maleate and furosemide tablet quality in Borena and Gedeo zones.
    Tesfaye E; Woldegiorgis F; Eticha T; Ashenef A
    PLOS Glob Public Health; 2024; 4(7):e0003104. PubMed ID: 39008465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of digitoxin tablets submitted by U.S. hospitals.
    Coffman HD; Crabbs WC; Jefferson EH; Page DP; Westenberger BJ
    Am J Hosp Pharm; 1983 Dec; 40(12):2161-4. PubMed ID: 6660231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parametric two-stage sequential quality assurance test of dose content uniformity.
    Tsong Y; Shen M
    J Biopharm Stat; 2007; 17(1):143-57. PubMed ID: 17219760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.